FDANonrulemakingFDA-2019-D-5255
Who commented on this docket
Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products; Draft Guidance for Industry; Availability
6 organizations filed 6 public comments on Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products; Draft Guidance for Industry; Availability, at the Food and Drug Administration. The comment window closed 2373d ago.
Organizations
6
Comments
6
RIN
—
Comment window
closed 2373d ago
Commenters (6)
- American Diabetes Associationtrade assoc.1 filing · confidence 85%
- American Pharmacists Association (APhA)trade assoc.1 filing · confidence 97%
- Association for Accessible Medicinestrade assoc.1 filing · confidence 97%
- Association for Accessible Medicines (AAM) and its Biosimilars Counciltrade assoc.1 filing · confidence 85%
- Eli Lilly and Companyunverified attribution1 filing · confidence 70%
- Vizient Inc.unverified attribution1 filing · confidence 70%
Attribution is name-based and imperfect. regulations.gov data is public record.